Fu Yuan, Yang Yixing, Fang Chen, Liu Xinming, Dong Ying, Xu Li, Chen Mulei, Zuo Kun, Wang Lefeng
Heart Center, Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Front Cardiovasc Med. 2022 Aug 30;9:944155. doi: 10.3389/fcvm.2022.944155. eCollection 2022.
This study was designed to explore the predictive value of plasma phenylalanine (Phe) and gut microbiota-derived metabolite phenylacetylglutamine (PAGln) in coronary in-stent restenosis (ISR).
Patients with coronary ISR, in-stent hyperplasia (ISH), and in-stent patency (ISP) were retrospectively enrolled in this study. Multivariable logistic regression analyses were used to identify independent risk factors of ISR. The predictive value of plasma Phe and PAGln levels was evaluated by receiver operating characteristic (ROC) curve analysis. The areas under the ROC curve (AUCs) were compared using the Z-test. The correlation between PAGln and clinical characteristics were examined using Spearman's correlation analysis.
Seventy-two patients (mean age, 64.74 ± 9.47 years) were divided into three groups according to coronary stent patency: ISR ( = 28), ISH ( = 11), and ISP ( = 33) groups. The plasma levels of Phe and PAGln were significantly higher in the ISR group than in the ISP group. PAGln was positively associated with the erythrocyte sedimentation rate, homocysteine, SYNTAX score, triglyceride to high-density lipoprotein ratio, Phe, and microbiota-related intermediate metabolite phenylacetic acid (PA). In the ISR group, with the aggravation of restenosis, PAGln levels were also elevated. In multivariate regression analyses, Phe, PAGln and SYNTAX score were independent predictors of coronary ISR (all < 0.05). In the ROC curve analyses, both Phe [AUC = 0.732; 95% confidence interval (CI), 0.606-0.858; = 0.002] and PAGln (AUC = 0.861; 95% CI, 0.766-0.957; < 0.001) had good discrimination performance in predicting coronary ISR, and the predictive power of PAGln was significantly better ( = 0.031).
Plasma Phe and PAGln are valuable indices for predicting coronary ISR, and gut microbes may be a promising intervention target to prevent ISR progression.
本研究旨在探讨血浆苯丙氨酸(Phe)和肠道微生物群衍生代谢物苯乙酰谷氨酰胺(PAGln)对冠状动脉支架内再狭窄(ISR)的预测价值。
本研究回顾性纳入了冠状动脉ISR、支架内增生(ISH)和支架内通畅(ISP)患者。采用多变量逻辑回归分析确定ISR的独立危险因素。通过受试者工作特征(ROC)曲线分析评估血浆Phe和PAGln水平的预测价值。使用Z检验比较ROC曲线下面积(AUC)。采用Spearman相关分析检测PAGln与临床特征之间的相关性。
72例患者(平均年龄64.74±9.47岁)根据冠状动脉支架通畅情况分为三组:ISR组(n = 28)、ISH组(n = 11)和ISP组(n = 33)。ISR组的血浆Phe和PAGln水平显著高于ISP组。PAGln与红细胞沉降率、同型半胱氨酸、SYNTAX评分、甘油三酯与高密度脂蛋白比值、Phe以及微生物群相关中间代谢物苯乙酸(PA)呈正相关。在ISR组中,随着再狭窄加重,PAGln水平也升高。在多变量回归分析中,Phe、PAGln和SYNTAX评分是冠状动脉ISR的独立预测因素(均P < 0.05)。在ROC曲线分析中,Phe [AUC = 0.732;95%置信区间(CI),0.606 - 0.858;P = 0.002]和PAGln(AUC = 0.861;95% CI,0.766 - 0.957;P < 0.001)在预测冠状动脉ISR方面均具有良好的辨别性能,且PAGln的预测能力显著更好(P = 0.031)。
血浆Phe和PAGln是预测冠状动脉ISR的有价值指标,肠道微生物可能是预防ISR进展的有前景的干预靶点。